Midazolam Pharmacokinetics in Morbidly Obese Patients Following Semi-Simultaneous Oral and Intravenous Administration: A Comparison with Healthy Volunteers

BACKGROUND: While in vitro and animal studies have shown reduced cytochrome P450 (CYP) 3A activity due to obesity, clinical studies in (morbidly) obese patients are scarce. As CYP3A activity may influence both clearance and oral bioavailability in a distinct manner, in this study the pharmacokinetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Brill, Margreke J. E., van Rongen, Anne, Houwink, Aletta P. I., Burggraaf, Jacobus, van Ramshorst, Bert, Wiezer, René J., van Dongen, Eric P. A., Knibbe, Catherijne A. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171595/
https://www.ncbi.nlm.nih.gov/pubmed/25141974
http://dx.doi.org/10.1007/s40262-014-0166-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171595/
https://www.ncbi.nlm.nih.gov/pubmed/25141974
http://dx.doi.org/10.1007/s40262-014-0166-x

Ejemplares similares